The participants are being asked to get this PET scan because the participants have ormay have cancer in the central nervous system (head, neck, or spine), and theinvestigator and the patient's physician thinks that this scan may provide usefulinformation for the participant's treatment.Primary ObjectiveTo provide expanded access to L-[11C]methionine as a positron-emitting tracer in childrenand young adults for the positron emission tomography (PET) imaging of neoplasms of thecentral nervous system (CNS) and head and neck to guide therapeutic management ofdisease.
Participants receive an intravenous injection of a small (tracer) dose of
L-[11C]methionine. Approximately 10 minutes later, patients undergo PET scanning to
evaluate localization of the tracer.
Drug: L-(11C) methionine
Injected intravenously with 20 mCi/1.7 sq m body surface area of L-[methyl-11C]methionine
(maximum prescribed dose: 20 mCi).
Other Name: methionine C 11
Inclusion Criteria:
- All participants under the care of a SJCRH physician with known or suspected
neoplastic disease of the CNS or head and neck are eligible for participation.
- No limit on age.
- Patients of all genders and all ethnic groups under the care of a SJCRH physician.
- Female participants of child-bearing age must not be lactating due to theoretical
potential harm to the infant from exposure to radiation.
- Informed consent signed by participant, parent, or guardian according to the
guidelines of the Institutional Review Board.
Exclusion Criteria:
- More than six L-[11C]methionine PET scans within the previous 12 months.
- Inability or willingness of patient, parent, or guardian to consent.
St. Jude Children's Research Hospital
Memphis, Tennessee, United States
Investigator: Barry L. Shulkin, MD, MBA
Contact: 866-278-5833
referralinfo@stjude.org
Investigator: Barry L. Shulkin, MD, MBA
Barry L. Shulkin, MD, MBA
866-278-5833
referralinfo@stjude.org
Barry L. Shulkin, MD, MBA, Principal Investigator
St. Jude Children's Research Hospital